Albany, NY -- (SBWire) -- 10/05/2018 --The global intravenous immunoglobulin (IVIG) market is prognosticated to witness solid growth in the coming years, according to report published by Transparency Market Research (TMR). The market's vendor landscape features high amount of consolidation. The leading four players, Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, held over two-thirds of the overall market share in 2017, with Grifols S.A. holding maximum traction in the market. The dominance of this company could be attributed to the strong geographical presence acquired by the company.
With a low number of vendors in the market, the market has an oligopolistic nature. This has fostered vigorous competition among the market participants. In order to ensure that the vendors leave their footprint in the industry, enterprises are adopting several strategies to gain market traction, such as mergers and acquisitions, and regional expansion. For instance, CSL Behring LLC recognized the large unmet demand for blood plasma and bio-therapeutics in Russia, and started operations in the country recently.
According to TMR's projections, the global market for intravenous immunoglobulin (IVIG) market is predicted to rise at an 8.5% CAGR over the forecast period of 2017 to 2024. The market, which stood at US$8419.7 mn in 2017, is expected to reach an estimated value of US$14,923 mn in 2024.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
The end-user segment of hospitals currently dominates the global IVIG market, accounting for over 60% of the overall market share. Geographically, North America is the leading regional market, holding over 45% of the market.
Surge in Number of Lifestyle Ailments to Propel Market
Sedentary lifestyle habits along with incrementing consumption of saturated fats, salt, sugars, less physical activities, and high alcohol consumption are contributing to the high prevalence of chronic lifestyle diseases. The growing ubiquity of lifestyle associated disorders such as obesity and antibody deficiency disorders are key factors anticipated to fuel the growth of the IVIG market in the forthcoming years.
The global intravenous immunoglobulin market is also witnessing a solid growth from the increasing number of patients with bleeding disorders, the surge in number of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients, and the expanding pool of geriatric population. Moreover, increasing spending habits of users in the healthcare sector is also positively impacting the growth of intravenous immunoglobulin market. Additionally, there has been increased adoption of technological innovations such as purification methods, advanced production technologies, and usage of off level indications. The swift uptake of such innovations are supporting the rapid growth of market. This is also responsible for providing rich opportunities to companies operating in the global intravenous immunoglobulin market.
Steep Therapy Costs to Deter Growth
Several administrative associations have imposed stringent guidelines for appropriate usage of intravenous immunoglobulin products. Moreover, the treatment costs associated with IVIG are considerably high, which could hamper the growth of intravenous immunoglobulin market to some extent. A large percentage of patients cannot afford intravenous immunoglobulin products, due to high cost of their treatment. Intravenous immunoglobulin products are very expensive as the materials required to produce them cost more and the manufacturing process requires a significant amount of blood samples from donors.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1930
On the other hand, according to the W.H.O, there are over 50 different Primary Immune Deficiency (PID's) such as specific antibody deficiency, X-lined hypo-gamma-globulinemia, and others at the present time, and these patients are in dire need of IVIG therapy. Further, the increase in approval of intravenous immunoglobulin (IVIG) drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin in the forthcoming years, fuelling market growth.
About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com
Intravenous Immunoglobulin Market: Rise in Prevalence of Autoimmune Disorders to Drive the Market